Vancouver, British Columbia--(Newsfile Corp. - October 3, 2017) - Valens GroWorks Corp. (CSE: VGW) (the "Company")
is pleased to announce a research partnership with UBC Okanagan and Thompson Rivers University. Dubbed the Cannabis Bio-products
Toolbox, this collaborative research project will explore the vast range of bioproducts that can be made from the plant - these
include pharmaceuticals, nutritional products, and industrial fibre.
The project has been awarded to Valens GroWork's Health Canada-licensed subsidiaries Valens Agritech and Supra THC Services, and
comes with a three-year $330,000 MITACS Research Grant. Research and analysis on cannabis plants and by-products will to be
supervised by Valens Agritech scientists Dr. Rob O'Brien and Dr. Yasantha Athukorala.
"Cannabis is a source of many potentially valuable products," says UBC Okanagan biology professor Michael Deyholos.
"But because of its prohibition over the past decades, development of new products from cannabis has lagged behind other
crops." Deyholos, whose research explores the potential of flax and hemp, says on the medicinal side of cannabis there are
dozens of compounds in the plant that may have specific health benefits. "Besides these pharmaceutical compounds, there are
healthful oils and proteins in the seed that we would like to enrich," he adds. "All of this requires a better understanding
of the genes and chemicals already present in different strains of cannabis, and that is what this project is designed to
do."
Deyholos says while cannabis is best known as a source of THC - the principal psychoactive ingredient in cannabis-the plant
produces at least 90 other cannabinoids - many of which have potent biological activities. Some of these compounds are being
examined for the treatment of cancer, Parkinson's disease, and other serious health conditions.
"Our team has experience in the characterization of a range of relevant biosynthetic pathways in cannabis stems," he
adds. The researchers want to breed strains that are enriched in various combinations of these compounds, tailored to the needs of
specific patients.
Deyholos is joined by UBC Okanagan biology professor Soheil Mahmoud, and UBC chemistry professor Paul Shipley - whose lab
examines the chemistry of medicinal plants, and Thompson Rivers University chemistry professor Bruno Cinel - a natural products
chemist. Together with a number of post-doctorate fellows and graduate students they will work at the Health Canada-licensed
laboratories of the Company's subsidiaries Valens Agritech and Supra THC Services in Kelowna.
"It is an honour to be associated with such a collection of accomplished scientists," says Valens Agritech President and
Chief Science Officer O'Brien. "The research derived from this funding will provide insights into the complexity of gene
expression in cannabis and will help produce new varieties that can have a greater health impact."
This work was supported by MITACS through the MITACS Accelerate Program.
"MITACS is by far the best funding program in support of intern placement," adds O'Brien. "It is a critical component
of Canada's success in the international marketplace."
About Valens GroWorks Corp.
Valens GroWorks Corp. is a CSE-listed company with an aggressive buildout strategy in progress. The Company seeks to capture a
broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D
clients, in pursuit of its ambitious seed-to-sale and farm-to-pharma objectives. The Company provides management, consulting,
testing and support services to domestic and international licensees, as well as financial support to fully-licensed third-party
operations.
The Company operates through two wholly-owned subsidiaries based in the Okanagan Valley of British Columbia: Valens Agritech
Ltd. ("VAL") holds a Health Canada Dealer's License and is positioning for expanded cannabis production, and Supra THC
Services Inc. ("Supra"), a Health Canada licensed cannabis testing lab providing sector-leading analytical and proprietary
services to Licensed Producers and ACMPR patients.
Supra, in collaboration with Thermo Fisher Scientific (Mississauga) Inc., is developing a "Centre of Excellence in Plant
Based Medicine Analytics" in Kelowna, British Columbia. For more information, please visit http://valensgroworks.com, http://www.valensagritech.com and http://www.suprathc.ca.
ABOUT THOMPSON RIVERS UNIVERSITY
Thompson Rivers University is committed to participating in community partnerships that drive the knowledge and innovation
economy in British Columbia's Southern Interior. Named after the view from its main Kamloops campus overlooking the junction of the
North and South Thompson rivers, TRU is proud to support the nearly 26,000 students on its campuses in Kamloops and Williams Lake,
and in online programming through TRU Open Learning.
With a 45-year history of excellence in education in the BC Interior, TRU prides itself on providing students with access to a
research-informed education, and providing our communities with access to the benefits of scholarly, research, and creative
activities that solve community problems and enrich community life.
ABOUT UBC's OKANAGAN CAMPUS
UBC's Okanagan campus is an innovative hub for research and learning in the heart of British Columbia's stunning Okanagan
Valley. Ranked among the top 20 public universities in the world, UBC is a globally recognized research-intensive institution whose
Okanagan campus was established in 2005.
The Okanagan campus emphasizes smaller class sizes, experiential learning, and research activity for students, combining a
world-class UBC degree with a tight-knit and entrepreneurial community. As part of North America's most international university,
the campus is home to 9,000 students representing 98 countries.
On behalf of the Board of Directors,
VALENS GROWORKS CORP.
(signed) "Tyler Robson"
Chief Executive Officer
For further information, please contact:
Greg Patchell
Telephone: +1.250.860.8634
Notice regarding Forward Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable
securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that
certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing
the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking
statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety
of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in
the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as
expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe
Harbour.
